IMAGE: Dr. Nathan Dolloff in his laboratory at the Medical University of South Carolina. Dr. Dolloff was recently awarded a phase 2 STTR grant to develop a compound to treat resistant… view more
Credit: Photograph by Emma Vought, Medical University of South Carolina
A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina (MUSC) startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, Ph.D. Dolloff is an assistant professor in the Department of Cell and Molecular Pharmacology & Experimental Therapeutics at MUSC and a member of MUSC Hollings Cancer Center. Dolloff and his team will use the STTR award to further develop the new compound into a drug that could be used with proteasome inhibitors in treatment-resistant multiple myeloma.
Proteasome inhibitors have contributed to the dramatic improvement in multiple myeloma treatment and outcomes over the past 15 years. They disrupt the normal ebb and flow of protein synthesis and breakdown in cells by blocking the activity of the proteasome, which is the cell’s major protein degradation machinery. This
Article originally posted at